BNP Paribas Asset Management
DFTX icon

BNP Paribas Asset Management’s Definium Therapeutics DFTX Stock Holding History

BNP Paribas Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.5K Sell
1,711
-101
-6% -$2.5K ﹤0.01% 1613
2026
Q1 		$34.2K Buy
1,812
+433
+31% +$7.35K ﹤0.01% 1869
2025
Q4 		$18K Buy
1,379
+587
+74% +$7.26K ﹤0.01% 1987
2025
Q3 		$9K Buy
792
+114
+17% +$1.06K ﹤0.01% 1671
2025
Q2 		$4K Buy
+678
New +$4.46K ﹤0.01% 2073

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BNP Paribas Asset Management's DFTX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Definium Therapeutics (DFTX) stake by 5.6% in Q2 2026, selling an estimated $2.5K and leaving 1,711 shares worth $80.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1613.

BNP Paribas Asset Management first reported a position in DFTX in Q2 2025 and has held it in 5 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • BNP Paribas Asset Management held 1,711 shares of Definium Therapeutics worth $80.5K as of Q2 2026.
  • BNP Paribas Asset Management sold 101 Definium Therapeutics shares in Q2 2026, an estimated $2.5K.
  • Definium Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1613 holding.
  • BNP Paribas Asset Management first reported a position in Definium Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.